Abstract
It is now well accepted that receptors can regulate cellular signaling pathways in the absence of a stimulating ligand, and inverse agonists can reduce this ligand-independent or “constitutive” receptor activity. Both the serotonin 5-HT2A and 5-HT2C receptors have demonstrated constitutive receptor activity in vitro and in vivo. Each has been identified as a target for treatment of schizophrenia. Further, most, if not all, atypical antipsychotic drugs have inverse agonist properties at both 5-HT2A and 5-HT2C receptors. This paper describes our current knowledge of inverse agonism of atypical antipsychotics at 5-HT2A/2C receptor subtypes in vitro and in vivo. Exploiting inverse agonist properties of APDs may provide new avenues for drug development.
Keywords: Antipsychotic drugs, atypical antipsychotic drugs, inverse agonism, constitutive activity, serotonin, 5-HT2A receptors, 5-HT2C receptors, schizophrenia.
Current Pharmaceutical Design
Title:Atypical antipsychotics and inverse agonism at 5-HT2 receptors
Volume: 21 Issue: 26
Author(s): Laura C. Sullivan, William P Clarke and Kelly A. Berg
Affiliation:
Keywords: Antipsychotic drugs, atypical antipsychotic drugs, inverse agonism, constitutive activity, serotonin, 5-HT2A receptors, 5-HT2C receptors, schizophrenia.
Abstract: It is now well accepted that receptors can regulate cellular signaling pathways in the absence of a stimulating ligand, and inverse agonists can reduce this ligand-independent or “constitutive” receptor activity. Both the serotonin 5-HT2A and 5-HT2C receptors have demonstrated constitutive receptor activity in vitro and in vivo. Each has been identified as a target for treatment of schizophrenia. Further, most, if not all, atypical antipsychotic drugs have inverse agonist properties at both 5-HT2A and 5-HT2C receptors. This paper describes our current knowledge of inverse agonism of atypical antipsychotics at 5-HT2A/2C receptor subtypes in vitro and in vivo. Exploiting inverse agonist properties of APDs may provide new avenues for drug development.
Export Options
About this article
Cite this article as:
Sullivan C. Laura, Clarke P William and Berg A. Kelly, Atypical antipsychotics and inverse agonism at 5-HT2 receptors, Current Pharmaceutical Design 2015; 21 (26) . https://dx.doi.org/10.2174/1381612821666150605111236
DOI https://dx.doi.org/10.2174/1381612821666150605111236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Concentration-Dependent Mechanisms of Adverse Drug Reactions in Epilepsy
Current Pharmaceutical Design Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States
Current Stem Cell Research & Therapy Early Detection, Intervention, and Prevention of Psychosis Program: Rationale, Design, and Sample Description
Adolescent Psychiatry Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease
Current Pharmaceutical Design Polyphenols: A Potential New Strategy for the Prevention and Treatment of Anxiety and Depression
Current Nutrition & Food Science The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Mindfulness in the Treatment of Adolescents with Problem Substance Use
Adolescent Psychiatry Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Novel Targets for Drugs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Review on Plants with Traditional Uses and Bio-activity against Hair Graying
Current Traditional Medicine Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases
Current Immunology Reviews (Discontinued) Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings
Current Drug Targets Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Current Pharmaceutical Design Directing the Antiretroviral Drugs to the Brain Reservoir: A Nanoformulation Approach for NeuroAIDS
Current Drug Metabolism Improving Human Performance and Comfort Through Perception: Technological Applications for Space
Recent Progress in Space Technology (Discontinued) Synthesis, Biological Evaluation and Molecular Docking of New Benzenesulfonylhydrazone as Potential anti-Trypanosoma cruzi Agents
Medicinal Chemistry The Role of Bioreactors in Cartilage Tissue Engineering
Current Stem Cell Research & Therapy Dysfunction of Magnocellular/dorsal Processing Stream in Schizophrenia
Current Psychiatry Research and Reviews Mouse Models of Myasthenia Gravis
Current Pharmaceutical Design